BAAM
CRDL

Baker Avenue Asset Management’s Cardiol Therapeutics CRDL Stock Holding History

Baker Avenue Asset Management’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-45,402
Closed -$49K – 641
2025
Q3 		$49K Buy
+45,402
New +$55.1K ﹤0.01% 618

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Baker Avenue Asset Management's CRDL Position: Q4 2025 in Review

Baker Avenue Asset Management sold out of Cardiol Therapeutics (CRDL) in Q4 2025, closing a stake of 45,402 shares — an estimated $49K sold.

Baker Avenue Asset Management first reported a position in CRDL in Q3 2025 and held it in 1 quarter. The position peaked at $49K in Q3 2025. 41 funds tracked by Wall St. Rank hold CRDL as of Q4 2025.

  • Baker Avenue Asset Management reported no remaining Cardiol Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Baker Avenue Asset Management sold 45,402 Cardiol Therapeutics shares in Q4 2025, an estimated $49K.
  • Baker Avenue Asset Management first reported a position in Cardiol Therapeutics in Q3 2025 and held it in 1 quarter.
  • Baker Avenue Asset Management's Cardiol Therapeutics position peaked at $49K in Q3 2025.
  • 41 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q4 2025.

Based on Baker Avenue Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.